Festschrift ArticleNonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer
Section snippets
Lesions and Complications
Many patients taking ASA or NSAIDs develop acute mucosal lesions in the stomach or duodenum, including petechia and erosions with little clinical consequences because most will not progress to ulcer complications and will not be associated with symptoms.6 Serious life-threatening events, including upper GI bleeding, perforation, and gastric outlet obstruction occur in approximately 1% to 1.5% of patients within the first 12 months of treatment with tNSAID. When symptomatic ulcers are included,
ACKNOWLEDGMENT
Dr. Angel Lanas has received research support or honoraria from Astra Zeneca, Pfizer, Bayer and Nicox.
REFERENCES (146)
Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years
Gastroenterology
(1997)- et al.
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
J Biol Chem
(1991) - et al.
A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
J Biol Chem
(1991) - et al.
A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin
Clin Ther
(2008) - et al.
Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer
Gastroenterology
(1998) - et al.
Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy
Am J Gastroenterol
(2000) - et al.
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis
Gastroenterology
(2002) - et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Lancet
(2004) - et al.
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison
Lancet
(1999) - et al.
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study
Am J Med
(2006)
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial
Gastroenterology
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial
Clin Gastroenterol Hepatol
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Lancet
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
Lancet
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis
Lancet
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
Lancet
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial
Lancet
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention
Lancet
Summing the risk of NSAID therapy
Lancet
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial
Lancet
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
J Am Coll Cardiol
Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors
Eur J Pharmacol
Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation
Gastroenterology
Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans
Gastroenterology
COX-1 and 2, intestinal integrity and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice
Gastroenterology
Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications
Gastroenterol Clin North Am
Blood and protein loss via small intestinal inflammation induced by nonsteroidal antiinflammatory drugs
Lancet
Glucose and citrate reduce the permeability changes caused by indomethacin in humans
Gastroenterology
Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs
Lancet
A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease
Gastroenterology
A low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment
Clin Gastroenterol Hepatol
Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding
Gastroenterology
Evidence of aspirin use in both upper and lower gastrointestinal perforation
Gastroenterology
Epidemiology of lower gastrointestinal bleeding
Best Pract Res Clin Gastroenterol
Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations
Am J Gastroenterol
Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case control study
Am J Gastroenterol
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study
Clin Gastroenterol Hepatol
Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy
Pharmacol Res
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use
Gastroenterology
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo
Clin Gastroenterol Hepatol
Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study
Clin Gastroenterol Hepatol
Update on gastrointestinal disorders associated with non-steroidal anti-inflammatory drugs
Gastroenterol Hepatol
The coxibs, selective inhibitors of cyclooxygenase-2
N Engl J Med
Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?
Expert Opin Ther Targets
Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies
Ann Med
Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality
Fam Pract
Prophylactic aspirin and risk of peptic ulcer bleeding
BMJ
Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use
Gut
Significant role of aspirin use in patients with esophagitis
J Clin Gastroenterol
Epidemiology of NSAID induced gastrointestinal complications
J Rheumatol
Cited by (80)
Synthesis, characterization and in vitro biological evaluation of novel organotin(IV) compounds with derivatives of 2-(5-arylidene-2,4-dioxothiazolidin-3-yl)propanoic acid
2020, Journal of Inorganic BiochemistryCitation Excerpt :2,4-Thiazolidinediones (TZDs) are a class of commercially available antidiabetic drugs with potential multifunctional targeting [38–40]. Moreover, propanoic acid derivatives such as ibuprofen, naproxen or ketoprofen belong to the class of non-steroidal anti-inflammatory drugs (NSAIDs) and also, as TZDs, possess ability to influence on different diseases [41]. The synthesis of combined molecules containing both biologically important chemical chores is very promising in terms of potential cumulative therapeutically effects, considering allo that TZDs and NSAIDs may induce cell apoptosis.
Rheumatoid arthritis: basic pathophysiology and role of chitosan nanoparticles in therapy
2020, Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological AgentsInfectious organisms associated with colorectal cancer
2019, Gastrointestinal Diseases and Their Associated InfectionsMicellar solubilisation enhances the antiinflammatory activities of curcumin and boswellic acids in rats with adjuvant-induced arthritis
2018, NutritionCitation Excerpt :Inflammation is one of the major causes of the development of various diseases like arthritis, cancer, cardiovascular disease, diabetes, obesity, osteoporosis, inflammatory bowel disease, asthma, and even central nervous system (CNS)-related diseases such as depression and Parkinson's disease [1]. Reports in the literature suggest that almost 90% of synthetic antiinflammatory drugs produce drug-related toxicities, iatrogenic reactions, and adverse effects compromising the treatment process [2,3]. Consequently, an immense interest has reemerged in herbs exerting antiinflammatory activity as potential alternative or concomitant tools for antiinflammatory treatment with much less side effects.
Synthesis, characterization and biological activity of 2-(5-arylidene-2,4-dioxotetrahydrothiazole-3-yl)propanoic acid derivatives
2017, Arabian Journal of ChemistryCitation Excerpt :Their therapeutic effects result from a selective inhibition of the enzyme cyclooxygenase-2 (COX-2), which is largely responsible for the production of prostaglandins in most pathological states (Talley et al., 2000). Numerous experimental, epidemiologic and clinical studies suggest that NSAIDs, particularly the highly selective COX-2 inhibitors, are potential anticancer agents (Cha and DuBois, 2007; Thun et al., 2002; Lanas, 2009). Beneficial effects of NSAIDs can be explained by an independent mechanism of action in relation to the COX-inhibition pathway (Tegeder et al., 2001), which is mediated through modulation of activity of various intracellular kinases including PPARγ inducing apoptosis (Liou et al., 2007; Baek et al., 2005; Wahl et al., 1998; Ho et al., 2003).
Anti-inflammatory and Anti-nociceptive Activities of African Medicinal Spices and Vegetables
2017, Medicinal Spices and Vegetables from Africa: Therapeutic Potential Against Metabolic, Inflammatory, Infectious and Systemic Diseases